Literature DB >> 26590918

Possible clinical effects of macrolides on the treatment of primary pulmonary mucosa-associated lymphoid tissue lymphoma.

Kazuhiro Yatera1, Yuji Ishimatsu2, Noriho Sakamoto3, Hiroshi Mukae4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26590918     DOI： 10.1007/s12185-015-1914-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  3 in total

1.  High-dose clarithromycin is an active monotherapy for patients with relapsed/refractory extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT): the HD-K phase II trial.

Authors:  A J M Ferreri; M Sassone; B Kiesewetter; S Govi; L Scarfò; G Donadoni; M Raderer
Journal:  Ann Oncol       Date:  2015-05-01       Impact factor: 32.976

2.  Rituximab monotherapy as a first-line treatment for pulmonary mucosa-associated lymphoid tissue lymphoma.

Authors:  Ikue Okamura; Hisao Imai; Keita Mori; Kazuto Ogura; Atsushi Isoda; Keichiro Mihara; Morio Matsumoto; Ryusei Saito; Toshiaki Takahashi; Takashi Ikeda
Journal:  Int J Hematol       Date:  2014-11-07       Impact factor: 2.490

3.  Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin.

Authors:  Yuji Ishimatsu; Hiroshi Mukae; Kiyoshi Matsumoto; Tatsuhiko Harada; Atsuko Hara; Shintaro Hara; Misato Amenomori; Hanako Fujita; Noriho Sakamoto; Tomayoshi Hayashi; Shigeru Kohno
Journal:  Chest       Date:  2010-09       Impact factor: 9.410
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.